Testing AD-229 in healthy adults
Part of Digestive system clinical trials.
This trial compares how two versions of the study drug AD-229 are processed by the body and how safe they are in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 19 and 55 years old (adult)
- Have a body mass index (BMI) between 18.5 and 29.9 (a healthy weight range)
- Weigh at least 50 kg (110 lbs)
- Be in good general health (no major medical conditions)
- Not have taken part in another drug study in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three similar drugs to see how they are processed by the body and how safe they are. It is for healthy volunteers to help find the best dose and form of these medications.
This trial tests a new drug (AD-115A or AD-1151) in healthy volunteers to see how safe it is and how the body processes it. If you qualify, you'll receive a single dose and be monitored closely.
This early-stage trial tests how a new drug called AD-230 moves through the body and whether it's safe in healthy volunteers. Researchers will measure drug levels in your blood and watch for any side effects.
This study tests a new drug called AD-230 to understand how your body absorbs and processes it, and whether food affects this process. You'll be a healthy volunteer helping researchers gather safety information.
This study tests how two experimental drugs, called AD-236A and AD-236B, interact in the body and checks if they are safe. Healthy volunteers are needed to see how the drugs affect each other.
This trial studies how two experimental drugs (AD-2321 and AD-2322) interact in the body and if they are safe for healthy volunteers. It is a Phase 1 study open to healthy adults.
Hear when a new Gastritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.